Table 1.
Cytopathological class of first and second EUS-FNA in patients who underwent repeat EUS-FNA for diagnosis of suspected pancreatic malignancy at St. Paul's Hospital, Vancouver, British Columbia, between 2007 and 2014.
| Cytopathological class | Second EUS-FNA | Total | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Indeterminate (I) | Negative (II) | Atypical (III) | Likely (IV) | Diagnostic (V) | NET | Lymphoma | |||
| First EUS-FNA | Indeterminate (I) | 5 | 8 | 6 | 1 | 2 | 0 | 0 | 22 |
| Negative (II) | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 5 | |
| Atypical (III) | 1 | 3 | 2 | 2 | 2 | 1 | 1 | 12 | |
| Likely (IV) | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 4 | |
| Diagnostic (V) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| NET | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | |
| Lymphoma | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | |
|
| |||||||||
| Total | 7 | 16 | 8 | 3 | 7 | 3 | 1 | 45 | |
Comparison of first and second EUS-FNA results in patients with suspected pancreatic cancer. Divided by cytopathological diagnosis (EUS-FNA: endoscopic ultrasound fine-needle aspiration; NET: neuroendocrine tumor).